Erratum to: OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity regardless of concomitant anticholinergic use or neurologic etiology (Advances in Therapy (2013) 30, (819-833) DOI:10.1007/s12325-013-0054-z);Onabotulinumtoxina is effective in patients with urinary incontinence due to neurogenic detrusor activity regardless of concomitant anticholinergic use or neurologic etiology

Advances in Therapy

Volumn 30, Issue 9, 2013, Pages 819-833

  Ginsberg, David ^a   Cruz, Francisco ^b   Herschorn, Sender ^c   Gousse, Angelo ^d   Keppenne, Véronique ^e   Aliotta, Philip ^f   Sievert, Karl Dietrich ^g   Brin, Mitchell F ^h,i   Jenkins, Brenda ^h   Thompson, Catherine ^j   Lam, Wayne ^h   Heesakkers, John ^k   Haag Molkenteller, Cornelia ^h  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b HOSPITAL DE SÃO JOÃO   (Portugal)

^c UNIVERSITY OF TORONTO   (Canada)

^d Memorial Hospital Miramar   (United States)

^e UNIVERSITY OF LIÈGE   (Belgium)

^f University of Tübingen ^*

^g UNIVERSITY OF TÜBINGEN   (Germany)

^h ALLERGAN INC   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j ALLERGAN PLC   (United States)

^k RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

more..

Author keywords

Botulinum toxin; Multiple sclerosis; Onabotulinumtoxina; Spinal cord injury; Urinary incontinence

Indexed keywords

BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT;

ARTICLE; AUTONOMIC DYSREFLEXIA; BACKACHE; CONSTIPATION; CYSTALGIA; DECUBITUS; DETRUSOR MUSCLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSURIA; FATIGUE; FEMALE; FEVER; HEADACHE; HEMATURIA; HUMAN; HYPERTENSION; INFLUENZA; INTERMITTENT CATHETERIZATION; KIDNEY CYST; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTIPLE SCLEROSIS; MUSCLE SPASM; MUSCLE WEAKNESS; NAUSEA; NEUROGENIC BLADDER; OVERACTIVE BLADDER; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL (TOPIC); PYELONEPHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; RHINOPHARYNGITIS; RISK ASSESSMENT; SPINAL CORD INJURY; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION; URODYNAMICS; UROSEPSIS;

ADULT; BOTULINUM TOXINS, TYPE A; CHOLINERGIC ANTAGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROMUSCULAR AGENTS; SPINAL CORD INJURIES; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE; URODYNAMICS;

EID: 84894345269     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-014-0103-2     Document Type: Erratum

References (15)

1. Foley SJ, McFarlane JP, Shah PJ. Vesico-ureteric reflux in adult patients with spinal injury. Br J Urol. 1997;79:888-91.
2. Hicken BL, Putzke JD, Richards JS. Bladder management and quality of life after spinal cord injury. Am J Phys Med Rehabil. 2001;80:916-22.
3. Schurch B, de Seze M, Denys P, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174:196-200.
4. Schurch B, Denys P, Kozma CM, et al. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol. 2007;52:850-8.
5. Apostolidis A, Thompson C, Yan X, Mourad S. An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity. World J Urol. 2012 (Epub ahead of print).
6. Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebocontrolled trial. Eur Urol. 2011;60:742-50.
7. Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187:2131-9.
8. Schurch B, Denys P, Kozma CM, et al. Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence. Arch Phys Med Rehabil. 2007;88:646-52.
9. Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184:2416-22.
10. Khan S, Game X, Kalsi V, et al. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J Urol. 2011;185:1344-9.
11. Kessler TM, Khan S, Panicker J, et al. Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life. Obstet Gynecol. 2009;113:1046-51.
12. Finney SM, Andersson KE, Gillespie JI, Stewart LH. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int. 2006;98:503-7.
13. Szollar SM, Lee SM. Intravesical oxybutynin for spinal cord injury patients. Spinal Cord. 1996;34:284-7.
14. Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol. 2006;49:644-50.
15. Karsenty G, Denys P, Amarenco G, et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/ neurogenic overactive bladder: a systematic literature review. Eur Urol. 2008;53:275-87.